Wuhan lab leak: Why scientists are interested in this Covid origin theory msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2021 Virtual Congress Corbus Pharmaceuticals Holdings, Inc. Norwood, Massachusetts, UNITED STATES
Norwood, MA, May 25, 2021 (GLOBE NEWSWIRE) Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the publication of two abstracts at the European League Against Rheumatism (EULAR) 2021 Virtual Congress that will be taking place June 2-5, 2021.
Details of the presentations are as follows:
Presentation Title
: Phase 3 Trial of Lenabasum, a CB2 Agonist, for the Treatment of Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Session: Progress in myositis and scleroderma research - I
Glucosidase inhibitors hold promise as novel therapeutic agents against SARS-CoV-2 preprint server, researchers from the United States report that two iminosugar glucosidase inhibitors have the ability to suppress the replication of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in tissue culture – at concentrations of at least 100 times lower than required for cytotoxic effects.
As the coronavirus disease 2019 (COVID-19) pandemic marches on, new antiviral agents effective against SARS-CoV-2 are urgently needed, despite a growing availability of vaccines. Remdesivir is still the only drug fully licensed for the treatment of affected individuals, but its effectiveness is controversial.
Iminosugar glucosidase inhibitors have their role in various viral diseases (e.g., hepatitis B and Ebola), as they prevent the folding process of a range of viral N-linked glycoprotein. Furthermore, they are competitive inhibitors of the host endoplasmic reticular (ER) glucosida
email article
Significantly more patients with moderate-to-severe pemphigus sustained their complete remission with rituximab (Rituxan) than with mycophenolate mofetil (MMF), a randomized trial showed.
At 1 year, 40% of patients treated with rituximab had sustained complete remission after ≥16 weeks off prednisone, as compared with 10% of patients randomized to MMF. Rituximab treatment was associated with a significantly reduced need for glucocorticoids and with a dramatic reduction in the number of disease flares.
Quality-of-life scores improved more with rituximab, but MMF was associated with fewer serious adverse events (SAEs), reported Victoria Werth, MD, of the University of Pennsylvania Perelman School of Medicine in Philadelphia, and colleagues in the